Former Coast Guard Rear Admiral Erica Schwartz has been nominated by President Donald Trump to lead the Centers for Disease Control and Prevention (CDC), according to multiple White House and federal agency announcements. The nomination follows an extended period of interim leadership at the nation’s premier public health agency, which has operated without a Senate-confirmed director since the departure of Dr. Mandy Cohen in early 2024.
Schwartz, a physician and public health officer with over three decades of service in the U.S. Coast Guard, most recently served as the Director of Medical Readiness and Training for the Coast Guard Health Services. Her nomination has drawn attention due to her military medical background and limited prior experience leading a civilian public health agency of the CDC’s scale and complexity.
The White House announced the nomination on May 15, 2024, stating that Schwartz’s expertise in operational medicine, disaster response, and federal healthcare systems makes her uniquely qualified to strengthen the CDC’s readiness for future health emergencies. If confirmed by the Senate, she would grow the first CDC director with a primary background in military medicine.
Trump nominates former Coast Guard doctor as CDC chief has become a focal point in discussions about the direction of U.S. Public health leadership, particularly as the agency continues to manage ongoing challenges related to respiratory illnesses, vaccination rates, and health equity initiatives.
Who Is Erica Schwartz?
Erica Schwartz graduated from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, and earned her medical degree before commissioning into the U.S. Coast Guard in 1990. She is board-certified in occupational medicine and has held increasing leadership roles within the Coast Guard’s health services division, overseeing medical readiness for over 40,000 active-duty and reserve personnel.
According to her official Coast Guard biography, Schwartz has deployed in support of humanitarian missions, including hurricane relief operations and migrant interdiction efforts. She received the Legion of Merit for her leadership during the Coast Guard’s response to the 2010 Haiti earthquake and has authored clinical guidelines on occupational health in maritime environments.
Prior to her nomination, Schwartz served as the Acting Assistant Secretary for Health at the Department of Health and Human Services (HHS) in an acting capacity during early 2024, a role that placed her in close coordination with CDC leadership during the transition period following Dr. Cohen’s departure.
Her nomination was formally submitted to the Senate on May 16, 2024, and referred to the Senate Health, Education, Labor, and Pensions (HELP) Committee for consideration. As of late May 2024, no date has been set for her confirmation hearing.
Context: CDC Leadership Vacancy and Interim Management
The CDC has been without a permanent, Senate-confirmed director since January 2024, when Dr. Mandy Cohen stepped down to return to academia in North Carolina. Following her departure, Dr. Debra Houry, the CDC’s Chief Medical Officer and Deputy Director for Program and Science, served as acting director.
In April 2024, Houry was reassigned to her substantive role, and the agency came under the day-to-day leadership of Dr. Christopher M. Jones, Director of the National Center for Injury Prevention and Control, who served in an acting capacity until Schwartz’s nomination. This interim arrangement marked one of the longest periods without a Senate-confirmed CDC director in the agency’s history.
The White House has stated that the nomination aims to restore stable, Senate-vetted leadership to the CDC as it continues to support national responses to influenza, RSV, and emerging variants of SARS-CoV-2, whereas also advancing initiatives in mental health, opioid prevention, and chronic disease reduction.
Public health experts have noted that prolonged interim leadership can affect agency morale, strategic planning, and external partnerships, particularly with state and local health departments that rely on consistent federal guidance and funding streams.
Reactions and Concerns from Public Health Leaders
The nomination has elicited a range of responses from public health professionals, former CDC officials, and congressional leaders. Some have praised Schwartz’s operational experience and crisis management background, particularly her work in coordinating medical responses during natural disasters and mass migration events.
Dr. Georges Benjamin, Executive Director of the American Public Health Association, said in a statement to APHA that while Schwartz brings valuable federal service experience, “the CDC requires a leader with deep expertise in epidemiology, vaccine science, and chronic disease prevention — areas where her public record is less documented.”
Others have raised questions about her lack of direct experience managing a large civilian public health bureaucracy or leading large-scale epidemiological investigations. Unlike previous CDC directors, Schwartz has not held academic appointments, led major research initiatives, or served in prominent roles at state or local health departments.
Senate Democrats, including Senator Patty Murray (D-WA), chair of the HELP Committee, have emphasized the need for a thorough vetting process, particularly regarding Schwartz’s views on public health autonomy, scientific integrity, and the CDC’s role in addressing health disparities.
As of May 2024, the White House has not released Schwartz’s complete financial disclosure or responses to the Senate committee’s questionnaire, which are standard prerequisites for scheduling a confirmation hearing.
What the CDC Does and Why Leadership Matters
The Centers for Disease Control and Prevention, headquartered in Atlanta, Georgia, is the United States’ national public health agency. It operates under the Department of Health and Human Services and is responsible for tracking disease outbreaks, setting vaccination guidelines, conducting health research, and providing technical support to state and local health departments.
The CDC plays a central role in national preparedness for pandemics, bioterrorism, and natural disasters. It also leads efforts in reducing chronic diseases such as diabetes and heart disease, promoting mental health, and preventing injuries and violence.
With an annual budget exceeding $9 billion and a workforce of over 15,000 employees across the U.S. And abroad, the CDC’s effectiveness depends heavily on stable, science-based leadership capable of navigating both public health complexities and federal bureaucratic processes.
A confirmed director is essential for the agency to access certain funding streams, enter into interagency agreements, and maintain credibility with international partners such as the World Health Organization.
Schwartz’s confirmation would mark a significant shift in the professional background traditionally associated with CDC leadership, which has historically included epidemiologists, infectious disease specialists, and academic physicians with strong research portfolios.
Next Steps in the Confirmation Process
The next formal step in the nomination process is a hearing before the Senate HELP Committee. As of May 28, 2024, no hearing date has been announced, though committee staff have indicated that proceedings are expected to initiate in June, contingent on the receipt of all required documentation from the nominee.
If approved by the committee, the nomination would proceed to a vote in the full Senate. A simple majority is required for confirmation. Given the current Senate composition, Republican support would be essential, though some bipartisan backing may be necessary depending on the nominee’s responses to questions about scientific independence and public health priorities.
The White House has stated that it remains confident in Schwartz’s ability to secure confirmation, citing her decades of federal service and nonpartisan reputation within the military medical community.
Until a director is confirmed, the CDC will continue to operate under acting leadership, with operational decisions made by senior career officials within the agency’s various centers and offices.
For updates on the nomination process, readers can monitor the Senate HELP Committee’s official website or the White House’s nominations database.
This developing story reflects broader debates about the qualifications needed to lead America’s public health infrastructure in an era of evolving health threats and political scrutiny. As the nation continues to recover from the impacts of the COVID-19 pandemic and confront new challenges in mental health, substance employ, and vaccine confidence, the leadership of the CDC remains a matter of national consequence.
We encourage readers to share their thoughts in the comments below and to spread awareness of this essential public health development by sharing this article on social media.